prednisone + cytarabine + vincristine

The combination of **prednisone**, **cytarabine**, and **vincristine** is a chemotherapy regimen developed and evaluated by **Shanghai Children's Medical Center** for the treatment of newly diagnosed multisystem Langerhans cell histiocytosis (MS-LCH) in children. This protocol was designed as a modification of the international LCH-II (Arm B) study, specifically investigating the efficacy of adding cytarabine to the standard induction backbone of prednisone and vincristine. Prednisone is a synthetic glucocorticoid that provides anti-inflammatory and immunosuppressive effects; cytarabine is an antimetabolite that inhibits DNA polymerase and interferes with DNA synthesis; and vincristine is a vinca alkaloid that inhibits microtubule formation, leading to mitotic arrest. The regimen aims to improve response rates and reduce disease reactivation, particularly in patients with or without risk organ involvement.

Other names

Cytarabine-containing protocol for LCHSCMC LCH protocolPrednisone + Cytarabine + Vincristine regimen